Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.

被引：4

作者：

Finn, Richard S.

Kudo, Masatoshi

Kang, Yoon-Koo

Yen, Chia-Jui

Galle, Peter R.

Llovet, Josep

Assenat, Eric

Brandi, Giovanni

Lim, Ho Yeong

Pracht, Marc

Rau, Kun Ming

Merle, Philippe

Motomura, Kenta

Ohno, Izumi

Daniele, Bruno

Shin, Dongbok

Gerken, Guido

Abada, Paolo

Hsu, Yanzhi

Zhu, Andrew X.

机构：

[1] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[2] Kindai Univ, Fac Med, Osaka, Japan

[3] Asan Med Ctr, Dept Oncol, Seoul, South Korea

[4] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[5] Univ Med, Mainz, Germany

[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[7] CHU Montpellier, Montpellier, France

[8] Univ Bologna, Dept Expt Diagnost & Specialty Med, Unit Oncol, Bologna, Italy

[9] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[10] Ctr Eugene Marquis, Rennes, France

[11] Kaohsiung Chang Gung Mem Hosp, Div Hematol Oncol, Kaohsiung, Taiwan

[12] Hop Croix Rousse, Dept Hepatol, Lyon, France

[13] Aso Iizuka Hosp, Fukuoka, Fukuoka, Japan

[14] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[15] G Rummo Hosp, Benevento, Italy

[16] Gachon Univ, Gil Med Ctr, Incheon, South Korea

[17] Univ Klinikum Essen AoR, Essen, Germany

[18] Eli Lilly & Co, Indianapolis, IN 46285 USA

[19] Eli Lilly & Co, New York, NY USA

[20] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.326

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

326

引用

页数：2

共 50 条

[31] Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein
Giannini, Edoardo G.
Trevisani, Franco
HEPATOBILIARY SURGERY AND NUTRITION, 2019, 8 (05) : 515 - 518
[32] Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
Masatoshi Kudo
Takuji Okusaka
Kenta Motomura
Izumi Ohno
Manabu Morimoto
Satoru Seo
Yoshiyuki Wada
Shinpei Sato
Tatsuya Yamashita
Masayuki Furukawa
Takeshi Aramaki
Seijin Nadano
Kazuyoshi Ohkawa
Hirofumi Fujii
Toshihiro Kudo
Junji Furuse
Hiroki Takai
Gosuke Homma
Reigetsu Yoshikawa
Andrew X. Zhu
Journal of Gastroenterology, 2020, 55 : 627 - 639
[33] RAMUCIRUMAB AS SECOND-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: ANALYSIS OF REACH PATIENTS BY ALBUMIN-BILIRUBIN (ALBI) GRADE
Blanc, J. -F.
Chan, S. L.
Park, J. O.
Ryoo, B. -Y.
Yen, C. -J.
Kudo, M.
Poon, R.
Pastorelli, D.
Baron, A.
Pfiffer, T. F.
Okusaka, T.
Kubackova, K.
Trojan, J.
Sastre, J.
Chau, I.
Abada, P.
Chang, S. -C.
Yang, L.
Zhu, A.
JOURNAL OF HEPATOLOGY, 2016, 64 : S693 - S694
[34] Overall survival (OS) in patients (pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): A real-world retrospective study.
Hennenfent, Kristin L.
Girvan, Allicia C.
Chaudhry, Aafia
Abada, Paolo
Sheffield, Kristin
Herren, Catherine K.
Raju, Aditya
Farrelly, Eileen
Bowman, Lee
Landsman-Blurnberg, Pamela
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[35] Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Analysis of REACH Trial Results by Child-Pugh Score
Zhu, Andrew X.
Baron, Ari David
Malfertheiner, Peter
Kudo, Masatoshi
Kawazoe, Seiji
Pezet, Denis
Weissinger, Florian
Brandi, Giovanni
Barone, Carlo A.
Okusaka, Takuji
Wada, Yoshiyuki
Park, Joon Oh
Ryoo, Baek-Yeol
Cho, Jae Yong
Chung, Hyun Cheol
Li, Chung-Pin
Yen, Chia-Jui
Lee, Kuan-Der
Chang, Shao-Chun
Yang, Ling
Abada, Paolo B.
Chau, Ian
JAMA ONCOLOGY, 2017, 3 (02) : 235 - 243
[36] Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.
Chau, Ian
Peck-Radosavljevic, Markus
Borg, Christophe
Malfertheiner, Peter
Seitz, Jean Francois
Park, Joon Oh
Ryoo, Baek-Yeol
Yen, Chia-Jui
Kudo, Masatoshi
Poon, Ronnie Tung-Ping
Pastorelli, Davide
Blanc, Jean-Frederic
Chung, Hyun Cheol
Baron, Ari David
Okusaka, Takuji
Cui, Zhanglin Lin
Girvan, Allicia C.
Abada, Paolo
Yang, Ling
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[37] Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
Finn, Richard S.
Yau, Thomas
Hsu, Chih-Hung
De Toni, Enrico N.
Goyal, Lipika
Galle, Peter R.
Qin, ShuKui
Rao, Sujata
Sun, Fangfang
Wang, Chunxiao
Widau, Ryan C.
Zhu, Andrew X.
ONCOLOGIST, 2022, 27 (12): : E938 - E948
[38] PATIENT-REPORTED OUTCOMES (PROS) WITH RAMUCIRUMAB VERSUS PLACEBO IN CHINESE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AND ELEVATED ALPHA-FETOPROTEIN FROM THE RANDOMIZED PHASE 3 REACH-2 STUDY
Chen, X.
Shao, G.
Bai, Y.
Gu, S.
Gu, K.
Zhang, Q.
Zhang, W.
Liu, J.
Zhou, L.
Qin, S.
VALUE IN HEALTH, 2022, 25 (12) : S19 - S20
[39] Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
Kudo, Masatoshi
Finn, Richard S.
Morimoto, Manabu
Rau, Kun-Ming
Ikeda, Masafumi
Yen, Chia-Jui
Galle, Peter R.
Llovet, Josep M.
Daniele, Bruno
Lim, Ho Yeong
McIlwain, David W.
Yoshikawa, Reigetsu
Nakamura, Kenichi
Liang, Kun
Wang, Chunxiao
Abada, Paolo
Widau, Ryan C.
Zhu, Andrew X.
LIVER CANCER, 2021, 10 (05) : 451 - 460
[40] Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
Ian Chau
Joon Oh Park
Baek-Yeol Ryoo
Chia-Jui Yen
Ronnie Poon
Davide Pastorelli
Jean-Frédéric Blanc
Masatoshi Kudo
Tulio Pfiffer
Etsuro Hatano
Hyun Cheol Chung
Katerina Kopeckova
Jean-Marc Phelip
Giovanni Brandi
Shinichi Ohkawa
Chung-Pin Li
Takuji Okusaka
Yanzhi Hsu
Paolo B. Abada
Andrew X. Zhu
British Journal of Cancer, 2018, 119 : 19 - 26

← 1 2 3 4 5 →